Previous 10 | Next 10 |
- VBI’s 3-antigen adult HBV vaccine available in the U.S. as PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and now approved in the European Union (EU)/European Economic Area (EEA) as PreHevbri™ [Hepatitis B vaccine (recombinant, adsorbed)] - New data from VBI&...
VBI Vaccines (NASDAQ:VBIV) said the European Commission (EC) granted marketing authorization to its vaccine PreHevbri for active immunization against infection caused by all known subtypes of the hepatitis B virus (HBV) in adults. The company said that it can also be expected that hepatitis D...
PreHevbri™ is the only approved 3-antigen hepatitis B vaccine for adults in the EU and EEA Approval follows the positive opinion granted by European Committee for Medicinal Products for Human Use (CHMP) in February 2022 Regulatory review in the United Kingdom is ongoing...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that tumor response and overall survival data from the ongoing Phase 2a study of VBI-1901, the Company’s ca...
- New Phase 1b clinical data of VBI-2905 (monovalent, Beta) demonstrated a well-tolerated safety profile and an encouraging ability to boost and broaden the immune response against the Beta variant - New preclinical data demonstrated VBI-2901 (trivalent, pan-coronavirus) induced antib...
VBI Vaccines (NASDAQ:VBIV) is trading ~8% higher in the premarket after it announced that its vaccine, PreHevbrio, would now be available in the United States, for active immunization against infections caused by all types of Hepatitis B virus in adults. The vacc...
Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...
- PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] is the only approved 3-antigen hepatitis B vaccine for adults in the U.S. - FDA approval of PreHevbrio received in November 2021 - PreHevbrio added to ACIP list of recommended adult HBV vaccines in February 2022 - Wholesale ...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the 32 nd ...
VBI Vaccines press release (NASDAQ:VBIV): FY GAAP EPS of $0.27 beats by $0.54. Revenue of $0.63M (-40.6% Y/Y) misses by $0.17M. As of December 31, 2021 cash, cash equivalents of $121.7M compared with $119.1 million in cash, cash equivalents, and short-term investments as of December...
News, Short Squeeze, Breakout and More Instantly...
Among the 7 patients on VBI-1901 treatment long enough to have 1+ MRI scan at the time of analysis, one partial tumor response (PR) and two stable disease (SD) observations have occurred as of May 15, 2024 The partial response, which demonstrated a 67% reduction in tumor size vs. baseline, wa...
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor response data from the ongoing randomized, controlled Phase 2b study of VBI-1901, the Company’s ca...
PreHevbrio ® (Hepatitis B Vaccine [Recombinant]) global net revenue increased 105% year-over-year in the first quarter of 2024 compared to the first quarter of 2023 Initial encouraging tumor response data from randomized Phase 2b study of VBI-1901 in recurrent glioblastoma (GBM) anno...